Thanks for that, OC!  Those words by Mika are reasonable and measured.  To me, the important point is that jumping to the NAS in and of itself does not ensure success, it may help marginally at best, but can be a cruel place if the company is not doing well.  The whole talk about the NAS in the Copetti days was merely to extend a carrot.  It was a complete fantasy at that point.

On the other hand, a whole lot of developmental biotechs live on the NAS and many have done great, well before FDA approval, hell, many who merely had encouraging results in a Phase 1 trial!